You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in the United Arab Emirates

Feb 2013

Price: US$2,400

About this Report

EXECUTIVE SUMMARY

Review period sees fluctuating performance

The review period saw a mixed performance for consumer health, with a number of different factors impacting sales growth. High inflation and currency fluctuations notably hindered sales growth in 2008, with constant value sales declining in this year. The self-medication trend boosted sales during the review period but was counterbalanced by consumers’ concerns over the safety of medicine. Economic worries in 2009 and 2010 meanwhile boosted sales of consumer health, with many consumers trading down from higher-priced Rx alternatives in these years.

Economic growth slows sales growth for consumer health

Rising economic confidence in 2011 did not, as might be expected, result in a stronger sales performance for consumer health. Indeed overall constant value sales growth slowed in comparison to the annual growth rates seen in 2009 and 2010. This was due to the widespread availability of Rx medicines, which can be purchased under-the-counter without a prescription from many chemists/pharmacies and parapharmacies/drugstores. As disposable income levels rose and consumers became more inclined to spend, many thus traded up from consumer health to higher-priced Rx medicines, which they regard as more effective.

Multinationals lead fragmented sales

Towards the end of the review period, the United Arab Emirates’ government announced plans to focus on lower-cost healthcare, as a result of the country’s ageing population and rising healthcare costs. However, for much of the review period the government gave priority to leading global brands in healthcare, with this preference being reflected in shares within consumer health. The top five players in 2011 in GBO terms were GlaxoSmithKline, Bayer, Novartis, Reckitt Benckiser and Boehringer Ingelheim. The leading domestic player is Julphar Gulf Pharmaceuticals but this company accounted for only a small share of overall value sales in consumer health in 2011 and lost share. Meanwhile, the widening range of economy imports, particularly generics, boosted the share of “others” to a dominant position in 2011.

Chemists/pharmacies continue to dominate but lose share

Chemists/pharmacies continued to dominate sales of consumer health at the end of the review period, with this reflecting the government’s strict restrictions on the distribution of many products. The second leading channel was meanwhile parapharmacies/drugstores, with these two channels together accounting for over 90% of value sales in 2011. However, these channels lost share as the distribution of consumer health continued to widen. Healthfood shops, “other” grocery retailers (primarily kiosks) and “other” non-grocery retailers such as fitness clubs, gyms and beauty specialist retailers all gained share in 2011, broadening their range of less-restricted products such as wound care or meal replacement slimming.

Stronger growth ahead for forecast period

The forecast period is expected to see slightly stronger constant value growth than that seen during the review period. This will be linked to economic growth and rising disposable income levels for low- and mid-income consumers, enabling these consumers to buy a widening range of consumer health. However, sales will continue to be constrained by a number of factors, including strong competition from under-the-counter Rx medicine sales, consumer safety concerns and limited distribution.


Samples (FAQs about samples):

doc_pdf.png Sample Consumer Health Market Research Report

doc_excel_table.png Sample Consumer Health Data

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in United Arab Emirates with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in United Arab Emirates, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in United Arab Emirates for free:

The Consumer Health in United Arab Emirates market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in United Arab Emirates?
  • What are the major brands in United Arab Emirates?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Table of Contents

Table of Contents

Consumer Health in the United Arab Emirates - Industry Overview

EXECUTIVE SUMMARY

Review period sees fluctuating performance

Economic growth slows sales growth for consumer health

Multinationals lead fragmented sales

Chemists/pharmacies continue to dominate but lose share

Stronger growth ahead for forecast period

KEY TRENDS AND DEVELOPMENTS

OTC faces strong competition from under-the-counter Rx sales

Rising disposable income levels encourage spending

High levels of obesity and overweight increasingly trouble consumers

Focus on cost reduction likely to boost domestic players

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2006-2011
  • Table 2 Life Expectancy at Birth 2006-2011

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2006-2011
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2006-2011
  • Table 5 Consumer Health Company Shares 2007-2011
  • Table 6 Consumer Health Brand Shares 2008-2011
  • Table 7 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
  • Table 8 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
  • Table 9 Forecast Sales of Consumer Health by Category: Value 2011-2016
  • Table 10 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016

APPENDIX

OTC registration and classification

Vitamins and dietary supplements registration and classification

Herbal/traditional products registration and classification

Self-medication/self-care and preventative medicine

Switches

DEFINITIONS

SOURCES

  • Summary 1 Research Sources

Consumer Health in the United Arab Emirates - Company Profiles

Arab Pharmaceutical Manufacturing Co in Consumer Health (United Arab Emirates)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 3 Arab Pharmaceutical Manufacturing Co: Competitive Position 2011

Julphar Gulf Pharmaceuticals in Consumer Health (United Arab Emirates)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 6 Julphar Gulf Pharmaceuticals: Competitive Position 2011

Riyadh Pharma Medical & Cosmetic Products Co Ltd in Consumer Health (United Arab Emirates)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 8 Riyadh Pharma Medical & Cosmetic Products Co Ltd: Competitive Position 2011

Adult Mouth Care in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • Adult mouth care saw only sluggish sales growth in 2011 over the previous year, with 5% current value growth mainly driven by inflation. Sales suffered due to low consumer awareness of these products, with adult mouth care seeing little advertising support or new product development. Manufacturers are unwilling to invest in adult mouth care due to low sales and sluggish sales growth.

SWITCHES

COMPETITIVE LANDSCAPE

  • Johnson & Johnson was the clear leader in adult mouth care throughout the review period and in 2011 accounted for 21% value share. The company offers the Oraldene and Daktarin brands, with these accounting for 15% and 6% value share respectively. These brands benefit from wide distribution via chemists/pharmacies, while Oraldene in particular is frequently recommended by doctors and pharmacists for inflammation, mouth ulcers, bad breath, sore throats and infections such as thrush.

PROSPECTS

  • Adult mouth care is expected to continue to be a largely neglected niche during the forecast period. Sales are expected to see just 8% constant value growth for the overall forecast period and will remain low at below AED4 million. Players will remain unwilling to invest in marketing or new product development in this area, due to low sales and sluggish sales growth. However, a lack of marketing support will create a vicious circle, with consumer awareness of these products remaining low. Consequently, constant value growth is expected to slow during the forecast period in comparison to the 11% growth seen during the review period.

CATEGORY DATA

  • Table 11 Sales of Adult Mouth Care: Value 2006-2011
  • Table 12 Sales of Adult Mouth Care: % Value Growth 2006-2011
  • Table 13 Adult Mouth Care Company Shares by Value 2007-2011
  • Table 14 Adult Mouth Care Brand Shares by Value 2008-2011
  • Table 15 Forecast Sales of Adult Mouth Care: Value 2011-2016
  • Table 16 Forecast Sales of Adult Mouth Care: % Value Growth 2011-2016

Analgesics in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • OTC analgesics continued to face strong competition from Rx alternatives in the United Arab Emirates at the end of the review period. Many chemists/pharmacies reportedly offer higher-strength Rx products under-the-counter. Many consumers meanwhile regard higher-strength products as more effective and are thus attracted by these products.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline was the clear leader in analgesics in 2011 and throughout the review period, accounting for close to a quarter of overall value sales. The company’s strength is primarily due to the Panadol brand, with the range accounting for 21% value share in overall analgesics in 2011. The company also offers leading topical analgesics/anaesthetic brand Calgel and third-ranked paediatric acetaminophen brand Calpol. GlaxoSmithKline thus benefits from offering well-established and well-regarded brands, with Panadol also benefiting from strong marketing support including TV advertising.

PROSPECTS

  • The government is expected to become increasingly strict in its controls over analgesics during the forecast period. September 2012 for example saw the government announce a new system to halt analgesic abuse across the United Arab Emirates, with this monitoring the distribution of analgesics and limiting doctors’ authority in prescribing these products. This month also saw the arrest of two doctors in Abu Dhabi, with these doctors having been coordinating with chemists/pharmacies to prescribe Rx drug Tramadol to people in return for cash and gifts.

CATEGORY DATA

  • Table 17 Sales of Analgesics by Category: Value 2006-2011
  • Table 18 Sales of Analgesics by Category: % Value Growth 2006-2011
  • Table 19 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2006-2011
  • Table 20 Analgesics Company Shares by Value 2007-2011
  • Table 21 Analgesics Brand Shares by Value 2008-2011
  • Table 22 Forecast Sales of Analgesics by Category: Value 2011-2016
  • Table 23 Forecast Sales of Analgesics by Category: % Value Growth 2011-2016

Calming and Sleeping in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • Calming and sleeping faced strengthening competition from Rx medicines towards the end of the review period. Only a handful of brands are available within OTC calming and sleeping, while well-known Rx alternatives such as Xanax and Librax are widely available under-the-counter from chemists/pharmacies. As the country’s economic situation improved in 2011, many consumers traded up from OTC to Rx products, viewing the latter as offering greater efficacy.

SWITCHES

COMPETITIVE LANDSCAPE

  • F Hoffmann La Roche was the clear leader in calming and sleeping throughout the review period and accounted for 43% value share in 2011. The company benefits from offering the Dormicum brand, which benefits from wide distribution and strong customer loyalty. Dormicum also benefits from a lack of strong competitors within OTC calming and sleeping, with the majority of calming and sleeping brands being categorised as Rx.

PROSPECTS

  • If the government fails to control under-the-counter sales of Rx calming and sleeping, OTC calming and sleeping is expected to see only sluggish sales growth during the forecast period. While the government made a high profile arrest of a pharmacist selling Rx sleeping pills in October 2012, this man was caught due to selling drugs from his car, with these having been stolen from the pharmacy where he worked. There is not expected to be a major clampdown on under-the-counter sales of Rx calming and sleeping via chemists/pharmacies in the first half of the forecast period.

CATEGORY DATA

  • Table 24 Sales of Calming and Sleeping: Value 2006-2011
  • Table 25 Sales of Calming and Sleeping: % Value Growth 2006-2011
  • Table 26 Calming and Sleeping Company Shares by Value 2007-2011
  • Table 27 Calming and Sleeping Brand Shares by Value 2008-2011
  • Table 28 Forecast Sales of Calming and Sleeping: Value 2011-2016
  • Table 29 Forecast Sales of Calming and Sleeping: % Value Growth 2011-2016

Cough, Cold and Allergy (Hay Fever) Remedies in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • There was a marked rise in the incidence of allergies during the review period, particularly allergic rhinitis. A study conducted by UAE University in 2010 for example found that allergic rhinitis affected 36% of people in Al Ain, making the ailment far more common than previously thought. The rising incidence of this ailment is thought to be partly linked to the widening use of green landscaping across the country, with a growing number of date palm trees, gardens and grass-covered areas as a result. However, increasing pollution also contributed to this trend, resulting in an increase in irritant dust in major cities. As a result, the incidence of allergic rhinitis is believed to be even higher in Dubai and Abu Dhabi. The incidence was higher among those of Arab ethnicity, possibly due to high levels of household cleanliness reducing natural exposure to germs but also due to these consumers’ lower exposure to many plants and their pollen.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline was the leading player in cough, cold and allergy (hay fever) remedies throughout the review period and accounted for 12% value share in 2011. The company’s strength is due to its well-advertised Panadol brand in combination products, where the company alone accounted for 28% value share in 2011. Panadol has had a longstanding presence in the United Arab Emirates and benefits from wide distribution and strong marketing support. The company lost share in 2009 and 2010 due to hoax emails warning against the use of Panadol. However, the brand regained its lost share by 2011, gaining half a percentage point over the previous year thanks to strong advertising support over these years.

PROSPECTS

  • Cough, cold and allergy (hay fever) remedies is expected to face growing competition during the forecast period, as consumers seek out what they believe to be safer alternatives. Home-made remedies are expected to see strong growth and widening media coverage, although these will continue to mainly be used in conjunction with standard cough, cold and allergy (hay fever) remedies. Vitamins and dietary supplements will also pose stronger competition as consumers take a more holistic approach to the prevention and cure of coughs, colds and flu, with consumers increasingly using products such as echinacea and vitamin C to battle these ailments.

CATEGORY DATA

  • Table 30 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 32 Sales of Decongestants by Category: Value 2006-2011
  • Table 33 Sales of Decongestants by Category: % Value Growth 2006-2011
  • Table 34 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 35 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 36 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2007-2011
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2008-2011
  • Table 38 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2011-2016
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2011-2016

Digestive Remedies in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • Sales of digestive remedies are strong in the United Arab Emirates, with strong sales linked to unhealthy eating habits. High levels of obesity are present in the country, partly as a result of a strong dependence on consumer foodservice and packaged meal solutions and partly due to rich and fatty cuisine and a strong focus on indulgence. There was thus a degree of maturity in digestive remedies by the end of the review period.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline was the clear leader in digestive remedies throughout the review period and accounted for 18% value share in 2011. This is due to the company’s Zantac and Tagamet brands in H2 blockers and Zofran in motion sickness remedies, with the company accounting for 54% and 14% value share respectively in these product areas in 2011. Zantac accounted for the bulk of the company’s sales and was the leading brand in digestive remedies in 2011 with 16% value share, thanks to its strong brand name and ongoing advertising support via regional satellite TV channels.

PROSPECTS

  • Unhealthy eating habits will continue to support strong sales of digestive remedies during the forecast period. While many consumers will seek to eat healthier diets, longer working hours and commutes will lead to busier consumer lifestyles. Consequently, consumers are expected to become more reliant on consumer foodservice and unhealthy packaged food.

CATEGORY DATA

  • Table 40 Sales of Digestive Remedies by Category: Value 2006-2011
  • Table 41 Sales of Digestive Remedies by Category: % Value Growth 2006-2011
  • Table 42 Digestive Remedies Company Shares by Value 2007-2011
  • Table 43 Digestive Remedies Brand Shares by Value 2008-2011
  • Table 44 Forecast Sales of Digestive Remedies by Category: Value 2011-2016
  • Table 45 Forecast Sales of Digestive Remedies by Category: % Value Growth 2011-2016

Ear Care in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • OTC ear care stagnated at the end of the review period, with this linked to strong competition from Rx medicines and home-made remedies. An improved economic performance in the country resulted in many consumers opting for Rx ear care rather than OTC variants, with Rx products being widely available under-the-counter and often recommended by many pharmacists. In addition, many consumers are unwilling to risk self-medication for serious ear problems and thus prefer to visit a doctor for advice.

SWITCHES

COMPETITIVE LANDSCAPE

  • There are four strong multinationals in ear care. Schering-Plough led sales throughout the review period and accounted for 17% value share with its Garason brand in 2011. Bristol-Myers Squibb followed, with its Kenacomb brand accounting for 15% value share, while Viatris and Rowa accounted for 12% value share each with the Xerumenex and Tropex brands respectively. These players have wide distribution and their brands offer a strong reputation for quality, thus garnering recommendations from doctors and pharmacists.

PROSPECTS

  • Ear care will continue to remain a sluggish niche during the forecast period. Sales will continue to face strong competition from Rx medicines, which will continue to be recommended frequently by pharmacists and to be widely available under-the-counter from chemists/pharmacies. Sales will also be hindered by many consumers’ unwillingness to self-medicate when it comes to serious ear problems and by a preference for home-made remedies for minor ear problems such as wax build-up.

CATEGORY DATA

  • Table 46 Sales of Ear Care: Value 2006-2011
  • Table 47 Sales of Ear Care: % Value Growth 2006-2011
  • Table 48 Ear Care Company Shares by Value 2007-2011
  • Table 49 Ear Care Brand Shares by Value 2008-2011
  • Table 50 Forecast Sales of Ear Care: Value 2011-2016
  • Table 51 Forecast Sales of Ear Care: % Value Growth 2011-2016

Eye Care in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • Eye care saw sluggish growth towards the end of the review period, with this linked to a lack of company investment in marketing or new product development. This is a largely mature niche, with low levels of consumer interest. The ongoing uptake of contact lenses also posed competition for eye care in 2011. As the economy improved, there was an 8% volume surge for contact lenses, which thus gained share from spectacles within eyewear. These consumers consequently use contact lens eye care, which is excluded from the scope of this report. Eye care thus saw 1% volume growth in 2011 over the previous year, with this being largely in line with the review period CAGR. Current value growth however slowed to below 6% in the year, in comparison to a review period current value CAGR of over 7%.

SWITCHES

COMPETITIVE LANDSCAPE

  • Allergan was the clear leader in eye care throughout the review period and in 2011 accounted for 19% value share. The company benefits from offering three strong brands in standard eye care, with Refresh, Celluvisc and Liquifilm Tears accounting for 10%, 10% and 8% value share respectively in 2011. These brands benefit from their wide distribution and strong reputation for quality, resulting in their frequent recommendation at chemists/pharmacies.

PROSPECTS

  • Eye care is not expected to see strong investment in consumer education campaigns during the forecast period or a flurry of new product development. This is a largely mature product area and players are thus unwilling to invest heavily in driving stronger growth. Eye care will also continue to face growing competition from contact lens eye care during the forecast period, as a growing number of consumers opt for monthly or daily contact lenses.

CATEGORY DATA

  • Table 52 Sales of Eye Care by Category: Value 2006-2011
  • Table 53 Sales of Eye Care by Category: % Value Growth 2006-2011
  • Table 54 Standard Eye Care by Format: % Value Breakdown 2007-2011
  • Table 55 Standard Eye Care by Positioning: % Value Breakdown 2007-2011
  • Table 56 Eye Care Company Shares by Value 2007-2011
  • Table 57 Eye Care Brand Shares by Value 2008-2011
  • Table 58 Forecast Sales of Eye Care by Category: Value 2011-2016
  • Table 59 Forecast Sales of Eye Care by Category: % Value Growth 2011-2016

Herbal/Traditional Products in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • Herbal/traditional products saw sales constrained throughout the review period by strong competition from standard OTC and also from unpackaged or home-made herbal remedies. Many consumers continue to view standard OTC as more effective and fast-acting in comparison to herbal/traditional products, resulting in insignificant sales for herbal/traditional products in systemic analgesics, calming and sleeping and digestive remedies. These products also accounted for just 4% value share or less in overall analgesics, cough, cold and allergy (hay fever) remedies, medicated skin care and vitamins and dietary supplements.

COMPETITIVE LANDSCAPE

  • Mentholatum was the leading player in herbal/traditional products throughout the review period and accounted for 16% of overall value sales in 2011. The company owes its lead to offering its eponymous brand in topical analgesics/anaesthetic, with this accounting for 47% of value sales in herbal/traditional analgesics in 2011. The company however saw the sharpest drop in value share in herbal/traditional products in 2011 over the previous year, dropping by almost three percentage points. This was due to a widening range of economy imports becoming available in herbal/traditional topical analgesics/anaesthetic at the end of the review period, particularly from India.

PROSPECTS

  • The government is keen to ensure that non-registered herbal/traditional products are unavailable in the country, notably recalling six herbal weight management products in January 2013 due to their use of unauthorised components. The government is also keen to encourage consumers to switch from unpackaged herbal remedies to herbal/traditional products and will thus continue to invest in consumer education campaigns highlighting unpackaged products’ low levels of quality and hygiene. As a result of these trends, many consumers are expected to switch from unpackaged products to packaged herbal/traditional products, while consumer confidence in the safety and efficacy of these products is also expected to rise.

CATEGORY DATA

  • Table 60 Sales of Herbal/Traditional Products: Value 2006-2011
  • Table 61 Sales of Herbal/Traditional Products: % Value Growth 2006-2011
  • Table 62 Herbal/Traditional Products Company Shares 2007-2011
  • Table 63 Herbal/Traditional Products Brand Shares 2008-2011
  • Table 64 Forecast Sales of Herbal/Traditional Products: Value 2011-2016
  • Table 65 Forecast Sales of Herbal/Traditional Products: % Value Growth 2011-2016

Medicated Skin Care in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • OTC medicated skin care suffered due to stronger competition from Rx medicines in 2011. As the country’s economic situation improved and consumers’ economic confidence rose, many traded up from OTC products to Rx alternatives. These products are widely available under-the-counter from chemists/pharmacies and, while more expensive, are generally regarded as more effective. This trend particularly impacted antiparasitics/lice (head and body) treatments, antipruritics, cold sore treatments and haemorrhoid treatments, which saw volume sales stagnate in 2011. 2011 consequently saw current value sales growth weaken to below 5%, with this representing considerably slower growth in comparison to a review period CAGR of 7%.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline led medicated skin care throughout the review period and accounted for 16% value share in 2011. This position was chiefly due to the company’s dominance of antipruritics with its Betnovate and Cutivate brands together accounting for 71% value share. The company also ranked third in medicated shampoos where Alphosyl accounted for 10% value share. These brands benefit from a longstanding presence and wide distribution.

PROSPECTS

  • Medicated skin care is expected to continue to see only sluggish growth during the forecast period. As the economy continues to grow and under-the-counter sales of Rx medicines continue unchecked, rising disposable income levels will encourage many consumers to trade up from OTC to Rx medicines. In addition, topical germicidals/antiseptics will continue to face strong competition from antiseptic beauty and personal care such as Dettol’s body wash/shower gel and bar soap. Meanwhile medicated shampoos will face strong competition from leading beauty and personal care brands of anti-dandruff shampoos, such as Procter & Gamble’s Head & Shoulders range.

CATEGORY DATA

  • Table 66 Sales of Medicated Skin Care by Category: Value 2006-2011
  • Table 67 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
  • Table 68 Medicated Skin Care Company Shares by Value 2007-2011
  • Table 69 Medicated Skin Care Brand Shares by Value 2008-2011
  • Table 70 Hair Loss Treatments Brand Shares by Value 2008-2011
  • Table 71 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
  • Table 72 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016

NRT Smoking Cessation Aids in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • The government of the United Arab Emirates progressively increased controls over smoking and tobacco products during the review period, following its ratification of the WHO’s agreement to limit demand for tobacco in 2005. In 2007, the government for example banned all grocery retailers from advertising tobacco products in-store. The government finally introduced a ban on smoking in most public places in 2010, with this including cars with passengers under 12-years-old. The government also invested heavily in public information campaigns highlighting the dangers of smoking during the review period.

SWITCHES

COMPETITIVE LANDSCAPE

  • Novartis and Johnson & Johnson battled for lead in NRT smoking cessation aids at the start of the review period, accounting for 19% and 18% value share respectively with their Nicotinell and Nicorette brands in 2006. However, by the end of the review period Novartis had become the clear leader with 35% value share, while Johnson & Johnson tailed behind with 20% share. Novartis benefited from working closely with the United Arab Emirates’ Ministry of Health during the review period, jointly operating a number of smoking cessation clinic. This strong connection with the government offered Nicotinell considerable prestige and attracted many consumers, while the brand is also more likely to be recommended by chemists/pharmacies as a result.

PROSPECTS

  • The government’s anti-smoking campaigns are expected to prove increasingly effective during the forecast period, with consumers becoming more aware of the links between smoking and health problems. Many consumers will also be encouraged to give up smoking by the gradual spread of the smoking ban across the country, with this legislation also becoming more consistently enforced. As a result, the percentage of adults that smoke is expected to decline during the forecast period, dropping by over half a percentage point overall to account for 26% of the population. The sharpest drop will be seen among women, with smokers among the female adult population dropping by almost two percentage points in share during the forecast period to account for just 22%. Women tend to be more receptive to healthy living messages in the United Arab Emirates than men and are also expected to be more concerned about links between smoking and skin ageing.

CATEGORY INDICATORS

  • Table 73 Number of Smokers by Gender 2006-2011

CATEGORY DATA

  • Table 74 Sales of NRT Smoking Cessation Aids by Category: Value 2006-2011
  • Table 75 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2006-2011
  • Table 76 NRT Gum Flavours: % Value Breakdown 2006-2011
  • Table 77 NRT Smoking Cessation Aids Company Shares by Value 2007-2011
  • Table 78 NRT Smoking Cessation Aids Brand Shares by Value 2008-2011
  • Table 79 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2011-2016
  • Table 80 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2011-2016

Sports Nutrition in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • Sports nutrition benefited from the health and wellness trend at the end of the review period. Strong media coverage of the country’s problems with excess weight and ensuing health problems encouraged a growing number of consumers to take up exercise. This trend resulted in sports nutrition seeing a stronger 7% current value growth in 2011 over the previous year in comparison to a review period CAGR of 5%.

COMPETITIVE LANDSCAPE

  • Optimum Nutrition is the dominant player in sports nutrition and accounted for 67% value share in 2011 with its eponymous brand. This is due to the company’s strong reputation in whey protein powder, with Optimum Nutrition 100% Whey Protein claiming to be “The World’s #1 Protein Powder.” The company also benefits from having the strongest and widest distribution presence in the United Arab Emirates, with a consistent presence for its range in many healthfood shops and gyms.

PROSPECTS

  • Sports nutrition is expected to move slightly further into the mainstream during the forecast period. As a widening range of healthfood shops stock these products, trial purchases are likely. In addition, a growing media and government focus on reducing obesity and increasing health will encourage more men and women to visit the gym on a regular basis. As a result, sports nutrition is expected to see a strong 5% constant value CAGR during the forecast period in comparison to the 6% constant value decline seen for the review period as a whole.

CATEGORY DATA

  • Table 81 Sales of Sports Nutrition: Value 2006-2011
  • Table 82 Sales of Sports Nutrition: % Value Growth 2006-2011
  • Table 83 Sports Nutrition Company Shares 2007-2011
  • Table 84 Sports Nutrition Brand Shares 2008-2011
  • Table 85 Forecast Sales of Sports Nutrition: Value 2011-2016
  • Table 86 Forecast Sales of Sports Nutrition: % Value Growth 2011-2016

Vitamins and Dietary Supplements in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • The health and wellness trend fuelled strong sales growth for vitamins and dietary supplements during the review period as a whole. However, towards the end of the review period health-conscious consumers became increasingly sophisticated in their understanding of nutrition. Many of these consumers turned their back on vitamins and dietary supplements and instead sought to gain full-spectrum nutrients from their diets such as by eating a larger quantity of fruit and vegetables. Among high-income consumers, there was also growing interest in vitamin injections, with some media reports claiming that the oral consumption of vitamins can feed microbes in the gut and thus do more harm than good.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Roche Holding continued to enjoy a strong lead in fragmented vitamins and dietary supplements sales at the end of the review period, accounting for over twice the value share of its closest competitor at 9%. The company benefits from offering a number of strong brands in vitamins and from offering a range of user-friendly formats, such as effervescent brands Redoxon in vitamin C and Berocca in multivitamins and drops and chew formats for Arovit in vitamin A. The company has wide distribution and its portfolio benefit from strong brand awareness.

PROSPECTS

  • The health and wellness trend is expected to support good growth for vitamins and dietary supplements during the forecast period. At the end of the review period, there was a shift away from vitamins and dietary supplements towards healthier eating and fortified/functional food and beverages. However, during the forecast period there is expected to be a shift back towards vitamins and dietary supplements. This trend will be encouraged by strong media coverage of these products and also by the United Arab Emirates’ reliance on imported fruit and vegetables, with many consumers being concerned about fresh food’s nutrient levels.

CATEGORY DATA

  • Summary 9 Dietary Supplements: Brand Ranking by Positioning 2010

CATEGORY DATA

  • Table 87 Sales of Vitamins and Dietary Supplements by Category: Value 2006-2011
  • Table 88 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2006-2011
  • Table 89 Dietary Supplements by Positioning 2006-2011
  • Table 90 Vitamins and Dietary Supplements Company Shares by Value 2007-2011
  • Table 91 Vitamins and Dietary Supplements Brand Shares by Value 2008-2011
  • Table 92 Vitamins Brand Shares by Value 2008-2011
  • Table 93 Dietary Supplements Brand Shares by Value 2008-2011
  • Table 94 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2011-2016
  • Table 95 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2011-2016

Weight Management in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • There is a large potential consumer base for weight management in the United Arab Emirates, due to high levels of overweight and obesity in the country. A fondness for indulgent food and a growing reliance on consumer foodservice and packaged meal solutions, coupled with low participation in exercise and a reliance on car travel, resulted in weight being a problem for the majority of consumers in the country. An estimated 25% of men and 42% of women aged 15-years-old and over were obese in the United Arab Emirates in 2010, with many more being overweight. The World Health Organisation meanwhile reported that an eighth of children were obese in 2010, with there also being a high share of overweight children. The percentage of overweight and obese consumers also continued to rise rapidly during the review period, due to busy but increasingly sedentary lifestyles and a growing reliance on consumer foodservice.

COMPETITIVE LANDSCAPE

  • General Nutrition Center was the sole player in weight management to have a double-digit value share at the end of the review period, with the company accounting for 13% value share. The company’s lead is due to the popularity of Slimquick Extreme, which attracts many women due to being specifically formulated to speed up female weight loss. The brand’s name and packaging attract many, with Slimquick Extreme being positioned as offering multifunctional weight loss benefits with the slogan “6 extreme ways women lose weight” underneath the words “metabolism,” “performance,” “energy,” “fat breakdown,” “water” and “appetite.” The brand also benefits from its use of high-power herbal ingredients, which offers it a more natural image.

PROSPECTS

  • Weight management will see a stronger performance during the forecast period, with constant value sales seeing a CAGR of 4% in comparison to the 2% CAGR seen during the review period. Stronger growth will be linked to widening consumer awareness of the dangers of excess weight, with a growing number of consumers seeking assistance in losing weight. The consumer base for weight management is expected to widen, with a growing number of men also showing an interest in these products as they seek to lose weight.

CATEGORY DATA

  • Table 96 Sales of Weight Management: Value 2006-2011
  • Table 97 Sales of Weight Management: % Value Growth 2006-2011
  • Table 98 Weight Management Company Shares 2007-2011
  • Table 99 Weight Management Brand Shares 2008-2011
  • Table 100 Forecast Sales of Weight Management: Value 2011-2016
  • Table 101 Forecast Sales of Weight Management: % Value Growth 2011-2016

Wound Care in the United Arab Emirates - Category Analysis

HEADLINES

TRENDS

  • Maturity in sticking plasters/adhesive bandages resulted in sluggish growth for overall wound care in 2011. Sticking plasters/adhesive bandages accounted for close to 100% of volume sales in the year and saw just 1% volume growth. Sales growth in this product area was boosted in 2009 and 2010 by the growing popularity of value-added variants such as Johnson & Johnson’s First Aid (Aloe Vera) and Beiersdorf’s Hansaplast Aqua Protect. However, consumers are typically unlikely to buy sticking plasters/adhesive bandages other than as replacement purchases, with this product area thus showing signs of maturity in 2011 following stronger growth in 2009 and 2010.

COMPETITIVE LANDSCAPE

  • Wound care is dominated by a trio of strong multinationals, with Johnson & Johnson accounting for 27% value share in 2011 and Beiersdorf and 3M following with 23% and 18% value share respectively. Johnson & Johnson offers the First Aid brand in gauze, tape and “other” wound care and Band-Aid in sticking plasters/adhesive bandages, accounting for 52% and 18% value share respectively in these product areas in the year. Beiersdorf and 3M meanwhile ranked first and second within sticking plasters/adhesive bandages with the Hansaplast and Nexcare brands accounting for 35% and 28% value share respectively. These players benefit from wide distribution and a strong reputation for quality.

PROSPECTS

  • There is expected to be a growing focus on self-medication during the forecast period, with government campaigns likely to encourage consumers to keep first aid kits at home. This trend will inevitably benefit packaged first aid kits the most, with this product area being forecast to see the strongest volume growth during the forecast period with a CAGR of 4%. However, sticking plasters/adhesive bandages and gauze, tape and “other” wound care will also benefit from consumers putting together their own basic first aid kits and also from replacement purchases for packaged first aid kits.

CATEGORY DATA

  • Table 102 Sales of Wound Care by Category: Value 2006-2011
  • Table 103 Sales of Wound Care by Category: % Value Growth 2006-2011
  • Table 104 Wound Care Company Shares by Value 2007-2011
  • Table 105 Wound Care Brand Shares by Value 2008-2011
  • Table 106 Forecast Sales of Wound Care by Category: Value 2011-2016
  • Table 107 Forecast Sales of Wound Care by Category: % Value Growth 2011-2016

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Paediatric Analgesics
            • Paediatric Acetaminophen
            • Paediatric Aspirin
            • Paediatric Combination Products - Analgesics
            • Paediatric Diclofenac
            • Paediatric Dipyrone
            • Paediatric Ibuprofen
            • Paediatric Ketoprofen
            • Paediatric Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Paediatric Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
      • Protein Products
        • Bars
        • Powder
        • RTD
        • Other Protein
      • Non-Protein Products
    • Vitamins and Dietary Supplements
      • Paediatric Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
          • Non-Herbal Dietary Supplements
            • Calcium Supplements
            • Co-Enzyme Q10
            • Combination Non-Herbal Dietary Supplements
            • Eye Health Supplements
            • Fish Oils
              • Cod Liver Oil
              • Other Fish Oils
            • Glucosamine
            • Mineral Supplements
            • Omega-3-6-9 (Fish and Non-Fish)
            • Probiotic Supplements
            • Protein Powder
            • Royal Jelly
            • Sam-E
            • Other Non-Herbal Dietary Supplements
          • Tonics and Bottled Nutritive Drinks
          • Vitamins
            • Multivitamins
            • Single Vitamins
              • Vitamin A
              • Vitamin B
              • Vitamin C
              • Vitamin D
              • Vitamin E
              • Other Single Vitamins
        • Weight Management
          • Meal Replacement Slimming
          • OTC Obesity
          • Slimming Teas
          • Weight Loss Supplements
          • Other Slimming Products
        • Herbal/Traditional Products
          • Herbal/Traditional Analgesics
          • Herbal/Traditional Calming and Sleeping Products
          • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
          • Herbal/Traditional Digestive Remedies
          • Herbal/Traditional Medicated Skin Care
          • Herbal/Traditional Medicinal Teas
          • Herbal/Traditional Smoking Cessation Aids
          • Herbal/Traditional Paediatric Dietary Supplements
          • Herbal/Traditional Dietary Supplements
          • Herbal/Traditional Tonics and Bottled Nutritive Drinks
        • Allergy Care
          • Allergy Eye Care
          • Antihistamines/Allergy Remedies (Systemic)
          • Paediatric Allergy Remedies
          • Topical Allergy Remedies/Antihistamines
        • Paediatric Consumer Health
          • Paediatric Analgesics
            • Paediatric Acetaminophen
            • Paediatric Aspirin
            • Paediatric Combination Products - Analgesics
            • Paediatric Diclofenac
            • Paediatric Dipyrone
            • Paediatric Ibuprofen
            • Paediatric Ketoprofen
            • Paediatric Naproxen
          • Paediatric Cough, Cold and Allergy Remedies
            • Paediatric Allergy Remedies
            • Paediatric Cough/Cold Remedies
          • Paediatric Digestive Remedies
            • Paediatric Diarrhoeal Remedies
            • Paediatric Indigestion and Heartburn Remedies
            • Paediatric Laxatives
            • Paediatric Motion Sickness Remedies
          • Paediatric Medicated Skin Care
          • Nappy (Diaper) Rash Treatments
          • Paediatric Vitamins and Dietary Supplements

      Statistics Included

      Statistics Included

      For each category and subcategory you will receive the following data in Excel format:

      From Passport

      • Market sizes
      • Company shares
      • Brand shares
      • Distribution
      • Analysis by format
      • Analysis by positioning
      • Analysis by type
      • Herbal/traditional vs standard
      • Pricing
      • Smoking population - number of adult smokers
      • Smoking prevalence - % of adult population

      Market size details:

      • Retail volume
      • Retail volume % growth
      • Retail volume per capita
      • Retail value retail selling price % growth
      • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
      • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price % growth
      • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY

      Methodology

      Methodology

      Global insight and local knowledge

      With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

      This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

      Industry specialists

      Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

      Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

      The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

      Country and regional analysts

      Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

      In-country research network

      To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

      Research Methodology

      Our research methods

      Each Euromonitor International industry report is based on a core set of research techniques:

      Desk research

      With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

      • National statistics offices governmental and official sources
      • National and international trade press
      • National and international trade associations
      • Industry study groups and other semi-official sources
      • Company financials and annual reports
      • Broker reports
      • Online databases
      • The financial, business and mainstream press

      Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

      Store checks

      Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

      • Place: We track products in all relevant channels, selective and mass, store and non-store
      • Product: What are innovations in products, pack sizes and formats?
      • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
      • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

      Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

      Trade survey

      Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

      Trade surveys allow us to:

      • Fill gaps in available published data per company
      • Generate a consensus view of the size, structure and strategic direction of the category
      • Access year-in-progress data where published sources are out of date
      • Evaluate the experts’ views on current trends and market developments

      In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

      Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

      Company analysis

      At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

      At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

      Forecasts

      Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

      Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

      Data validation

      All data is subjected to an exhaustive review process, at country, regional and global levels.

      The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

      Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

      Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

      Market analysis

      Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

      Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

      my pages

      Want to find out more about this report?

      If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!